Price Of Alzheimer’s Drug Aduhelm Halved To $28,200
News outlets report on Biogen's reaction to "slower-than-expected" U.S. sales. Hospitals have complained that the controversial drug's high cost wasn't worth its benefits. Biogen is also seeking to save $500 million in costs across the company next year.